1 / 2

GLOBE: Efficacy at Year 2, HBeAg-Positive Patients ITT Population

GLOBE: Efficacy at Year 2, HBeAg-Positive Patients ITT Population. *designates P <0.05, telbivudine vs lamivudine at Week 104. Adapted from AASLD 2006. GLOBE: Viral Load/Resistance at 24 Weeks. HBeAg Positive. HBeAg Negative. 100. 90. Telbivudine Lamivudine. 80. 70. 60. 56. 60. 50.

faraji
Download Presentation

GLOBE: Efficacy at Year 2, HBeAg-Positive Patients ITT Population

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. GLOBE: Efficacy at Year 2,HBeAg-Positive Patients ITT Population *designates P<0.05, telbivudine vs lamivudine at Week 104. Adapted from AASLD 2006.

  2. GLOBE: Viral Load/Resistance at 24 Weeks HBeAg Positive HBeAg Negative 100 90 Telbivudine Lamivudine 80 70 60 56 60 50 45 50 Percent with Resistance 41 40 30 29 25 30 24 20 20 12 9 6 5 10 4 2 0 < QL QL - 3 3 to 4 > 4 < QL QL - 3 3 to 4 > 4 n = 203 146 57 63 83 79 115 175 178 157 18 20 16 24 10 23 Serum HBV DNA Level at Week 24 Presented at AASLD 2007.

More Related